Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD...
Argus Research analyst Jasper Hellweg maintains Sanofi (NASDAQ:SNY) with a Buy and raises the price target from $55 to $60.
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last q...
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a...
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead t...
Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment T...
2024 business EPS guidance upgraded • 2024 business EPS(1) to be stable at CER(2), an upgrade from a low single-digit percentag...
